CEO on reduced guidance: "We could make heaps of money, but it would kill the growth"
CEO of Chemometec Michael Eising anticipates significantly lower growth, especially on the bottom line, in the coming year. Instead, the company will invest in new instruments to ensure a healthy business in future.
During the past years, Danish medtech company Chemometec has generated booming growth rates on the top line and bottom line as well as the stock market. However, expectations for the coming year are more modest, reveals the company's latest annual report.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
